Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 14 results:
Συντάκτης Τίτλος [ Τύπος] Έτος Φίλτρα: Συντάκτης is Vlachaki, Efthimia [Clear All Filters]
Combined chelation therapy with deferoxamine and deferiprone in β-thalassemia major: compliance and opinions of young thalassemic patients..
Hemoglobin. 38(2), 111-4.
(2014). Is deferasirox implicated in multiple organ failure in a patient with homozygous β-thalassemia?.
Angiology. 62(4), 346-8.
(2011). Diffuse gastric plasmacytoma involvement in multiple myeloma..
Endoscopy. 47 Suppl 1 UCTN, E197.
(2015). Elevated serum parathormone levels are associated with myocardial iron overload in patients with beta-thalassaemia major..
Eur J Haematol. 84(1), 64-71.
(2010). Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients..
Pharmacogenomics. 20(11), 791-801.
(2019). Hemoglobinopathies and COVID-19: The Experience of a Center in Northern Greece..
Hemoglobin. 46(2), 143-145.
(2022). Is liver stiffness really unrelated to liver iron concentration?.
Br J Haematol. 150(2), 247-8.
(2010). MRI assessment of liver iron content in thalassamic patients with three different protocols: comparisons and correlations..
Eur J Haematol. 82(5), 388-92.
(2009). Parotid gland oncocytoma: a case report..
Cases J. 2, 6423.
(2009). Poor correlations between measurements of bone quality by quantitative ultrasound sonography and dual energy X-ray absorptiometry in patients with beta-thalassaemia major..
Eur J Haematol. 82(1), 15-21.
(2009). Restrictive pulmonary dysfunction and its predictors in young patients with β-thalassaemia major..
Pediatr Pulmonol. 47(8), 801-7.
(2012). Safety and efficacy of combination therapy with pegylated interferon alpha-2a and ribavirin in treating patients with chronic hepatitis C and beta-thalassaemia major: a Greek single-center experience..
Acta Haematol. 126(4), 231-3.
(2011). Safety of deferasirox in sickle cell disease patients with co-existing liver impairment..
Br J Haematol. 157(4), 505-6; author reply 506-7.
(2012). β-Thalassemia and renal complications. A narrative review of pathophysiologic mechanisms.
Integrative Molecular Medicine. 5(4),
(2018).